CN

CN
Clinical Solutions
Clinical Solutions
Professional Clinical Medical Solutions
Clinical Solutions
Stroke, The Greatest Risk of Atrial Fibrillation (AF)

Atrial fibrillation, one of the most common arrhythmias in clinical practice, refers to the loss of regular, organized electrical activity in the atria, replaced by rapid, irregular fibrillation waves. It is typically characterized by an irregular and fast heart rate, caused by the atria losing their normal rhythm. Organic heart disease, autoimmune diseases, trauma, smoking, alcohol abuse, and family history are all factors that can lead to AF. Thromboembolism is the most significant complication of AF, with the highest incidence and greatest harm being stroke.

 

Studies have shown that 90% of thrombi in non-valvular AF patients originate from the left atrial appendage (LAA). A large data study on LAA thrombus before pulmonary vein isolation in 2019 once again confirmed that 100% of thrombus formation in AF patients originates from the LAA.

 

1.AF causes blood to stagnate in the LAA, gradually forming a thrombus

2.The unique anatomy of the LAA and its uneven internal musculature create eddies in the blood, promoting thrombus formation

3.Thrombi dislodge from the LAA and enter the arterial system

4.Thrombi become lodged in the cerebral vasculature, restricting blood flow and causing stroke

Stroke, The Greatest Risk of Atrial Fibrillation (AF)
Clinical Solutions
Left Atrial Appendage Closure (LAAC)


Left Atrial Appendage Closure (LAAC) is a minimally invasive interventional treatment method that involves inserting a catheter through the femoral vein in the thigh to deliver a closure device to the left atrial appendage(LAAC). The closure device can unfold  like an umbrella while reaching the LAAC  to seal it off..In this way, even if thrombi form or become dislodged post-procedure, the closure device can isolate them within the LAAC , preventing them from dislodging or even traveling throughout the vasculature to avoid the risk of thromboembolic events. LAAC not only does not increase the bleeding risk for patients with atrial fibrillation., but also has its advantage in achieving anticoagulant effects while eliminating the patients' dependence on long-term oral anticoagulation therapy compared to anticoagulation medications, which offers a new treatment option for patients who cannot or do not wish to undergo long-term anticoagulation therapy and those at high risk of bleeding.



Privacy settings

This website may store cookies on your browser. Cookies are mostly used to make the website work asyou expect it to. No cookie will directly identify you, but it can give you a more personalized browsingexperience.


CardioFlow Medtech respects your privacy rights, so you can block some types of cookies. Technically non-essentialcookies and tracking mechanisms, that enable us to provide you with customized offers (marketingcookies), are only used if you have given prior consent to such use.

By clicking "Save", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.

×
TOP

©Copyright 1998-2023, MicroPort CardioFlow Medtech Corporation. All rights reserved. | 网站备案/许可证号:沪ICP备2023023560号 沪公网安备 31011502014876号

互联网药品信息服务资格证书编号:(沪)-非经营性 - 2024 - 0135

“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.